OUTLINE:
Participants undergo collection of blood, urine, and/or tissue samples every 6-12 months, when any biopsy occurs, and if relevant, at time of curative therapy and 3-9 months after completion of curative therapy for up to 3 years.
Age
40–any
Sex
MALE
Healthy volunteers
Accepted
You may be eligible if
People with prostates ≥40 years of age
Documented germline pathogenic variant in known or suspected genes associated with prostate cancer risk.
You may not be if
Prior diagnosis of prostate cancer
Medical contraindication to any of the study procedures (e.g., prostate biopsy)
For all cancer types except non-melanoma skin cancer, any cancer treatment with curative intent within the past 12 months (e.g., surgery, radiation, chemotherapy, immunotherapy)
Prior or concurrent participation in an interventional clinical trial aimed at preventing cancer for people with germline variants associated with increased prostate cancer risk
Unable to provide written informed consent
Unable or unwilling to complete clinical care and study procedures as indicated by the study protocol.
Clareo Health | Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease, PATROL Study
